Gilead Sciences (GILD) Total Liabilities (2009 - 2026)

Gilead Sciences (GILD) has reported Total Liabilities for 18 consecutive years, with $32.8 billion the latest figure, recorded in Q1 2026.

• Total Liabilities for Q1 2026 came in at $32.8 billion, down 12.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.8 billion (down 12.3% YoY), and the FY2025 annual result was $36.3 billion, down 8.63% from the prior year.
• Total Liabilities was $32.8 billion for Q1 2026 at Gilead Sciences, down from $36.3 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $43.2 billion in Q1 2022 and troughed at $32.8 billion in Q1 2026.
• Average Total Liabilities over 5 years is $38.9 billion, with a median of $39.4 billion recorded in 2023.
• Year-over-year, Total Liabilities dropped 14.21% in 2024 and gained 2.37% in 2025.
• Over 5 years, Total Liabilities stood at $42.0 billion in 2022, then declined by 6.16% to $39.4 billion in 2023, then increased by 0.95% to $39.7 billion in 2024, then dropped by 8.63% to $36.3 billion in 2025, then dropped by 9.79% to $32.8 billion in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $32.8 billion in Q1 2026, $36.3 billion in Q4 2025, and $37.0 billion in Q3 2025.